Novo Nordisk stock gains as FREHEMGO and AI partnership sharpen growth story

Published on 09/19/2026 at 12:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock trades around USD 46.98 on September 18, 2026 amid a consensus Hold rating and an average analyst price target of USD 46.42. The company reported first-half 2026 net sales up 13% to DKK 175.3 billion and operating profit up 20%.

Modernes nordisches Forschungszentrum, Glasfassade, Skandinavisches Architekturdesign — Novo Nordisk A/S (DK0062498333): nordisches Forschungszentrum mit Glasfassade und klaren skandinavischen Linien, Illustration mit AI erstellt.

Novo Nordisk stock (ISIN DK0062498333) is trading near USD 46.98 on the New York Stock Exchange on September 18, 2026, reflecting a gain of 2.20% intraday and keeping the shares close to the mean analyst price target of USD 46.42.

Regulatory and strategic catalysts drive Novo Nordisk

As The Globe and Mail reported on September 18, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending EU marketing authorisation for Novo Nordisk's haemophilia A therapy FREHEMGO for adults and children, with or without inhibitors.

This regulatory momentum complements a strategic push into artificial intelligence, as Barchart highlighted on September 18, 2026, noting Novo Nordisk's partnership with Anthropic to use AI models and Claude Science to accelerate drug discovery and software engineering.

First-half 2026 figures show double-digit growth

According to Barchart, Novo Nordisk reported net sales of DKK 175.3 billion for the first half of fiscal year 2026, an increase of 13% year over year.

For the same period, operating profit reached DKK 86.7 billion, up 20% compared with the first half of fiscal year 2025, indicating margin expansion as earnings grew faster than revenue.

The same analysis notes that free cash flow for the second quarter of fiscal year 2026 came in at DKK 42.5 billion, giving Novo Nordisk significant financial flexibility to invest in clinical trials and market penetration initiatives.

Analyst views and price targets frame expectations

Based on 23 analysts tracked in the overview cited by Barchart, Novo Nordisk stock carries a consensus Hold rating, with one Strong Buy recommendation, 19 Hold ratings and three Strong Sell ratings.

The same source reports a mean price target of USD 46.42, implying potential upside of about 7% from the current intraday level of USD 46.98 as of September 18, 2026, while the most bullish target of USD 55.23 suggests upside of around 18.3% from that price.

Separately, MarketBeat notes on September 19, 2026 that NVO stock opened at USD 43.23 on the prior trading day and indicates a separate consensus rating of Hold with an average price target of USD 64.94, underscoring that estimates vary significantly across platforms.

Market backdrop in diabetes and obesity care

The growth context is substantial: Barchart cites Novo Nordisk's estimates that more than 550 million people are living with type 1 and type 2 diabetes worldwide and over 900 million people are living with obesity.

Despite this large addressable market, only about 1% of people with obesity globally are treated with branded anti-obesity medicines and roughly 9% of total estimated diabetes prescriptions are for GLP-1 therapies, leaving considerable room for Novo Nordisk to increase penetration in its key therapeutic areas.

The same report points out that Novo Nordisk has a robust pipeline with 12 drug candidates each in phase 1, phase 2 and phase 3 trials, plus six filed candidates, supporting long-term growth prospects in obesity, diabetes, rare blood disorders and rare endocrine disorders.

Stock price level and trading data

On the New York Stock Exchange, Novo Nordisk's American depositary shares traded at USD 46.98 as of 11:26 a.m. Eastern time on September 18, 2026, representing a 2.20% increase on the day compared with the prior close, according to price data from Nasdaq real-time quotes displayed by Yahoo Finance.

An additional cross-venue snapshot from Interactive Investor on September 18, 2026 showed Novo Nordisk shares in Copenhagen at DKK 284.20, up 1.7% intraday, and the New York listing at USD 43.60, up 1.0% in pre-market trading, indicating that the stock has been recovering from a 12-month decline of about 28% in Copenhagen and 30% in New York.